Brain Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium, Inc., Bristol-Myers Squibb,

Brain Cancer Pipeline constitutes 10+ key companies continuously working towards developing 10+ Brain Cancer treatment therapies, analyzes DelveInsight.

Brain Cancer Overview:

Brain metastases occur in 10-16% of patients with metastatic breast cancer and are typically linked to a poor prognosis. The risk of developing brain metastases is higher in younger patients, and in those with estrogen receptor-negative tumors, Her-2+ tumors, or basal-like tumors. Diagnosis is usually made through brain MRI (magnetic resonance imaging), and in rare cases, a biopsy is performed to confirm the diagnosis. Additional diagnostic methods include neuroimaging, staging, and neuropathology. Treatment generally involves whole brain radiation, or a combination of stereotactic radiosurgery or surgery followed by whole brain radiation, resulting in a roughly 20% survival rate after one year. The blood-brain barrier presents a significant challenge in delivering chemotherapy to the brain. However, etirinotecan pegol has shown promising results under chemotherapy, and targeted therapies like Abemaciclib are also emerging. Lapatinib, a small molecule with potential to cross the blood-brain barrier, has been widely tested for treating HER2-positive brain metastases.

Request for a detailed insights report on Brain Cancer pipeline insights @ https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Brain Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Brain Cancer Therapeutics Market.

Key Takeaways from the Brain Cancer Pipeline Report

DelveInsight's Brain Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Brain Cancer treatment.
In December 2024, Kazia Therapeutics' stock dropped by 26%, falling to $2.28, after the FDA indicated it might only approve the company's brain cancer treatment, paxalisib, through standard approval rather than granting accelerated approval. This decline followed a 48% decrease in the stock's value earlier in the year. Paxalisib, designed to treat glioblastoma, showed significant improvements in overall survival in a July trial, which had previously caused a surge in the company's stock price.
In April 2024, the US FDA granted accelerated approval to Day One Biopharmaceuticals' OJEMDA (tovorafenib) for treating patients aged 6 months and older with certain relapsed or refractory pediatric low-grade glioma.
In April 2024, TME Pharma received Fast Track Designation from the US FDA for NOX-A12 (olaptesed pegol), a CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for the treatment of glioblastoma, an aggressive form of adult brain cancer.
In February 2024, Servier announced that the US FDA had accepted the filing and granted priority review for the New Drug Application (NDA) for vorasidenib. If approved, vorasidenib would become the first targeted therapy for patients with IDH-mutant gliomas, with a Prescription Drug User Fee Act (PDUFA) action date set for August 20, 2024.
Key Brain Cancer companies such as Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium, Inc., Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others are evaluating new drugs for Brain Cancer to improve the treatment landscape.
Promising Brain Cancer pipeline therapies in various stages of development include ANG1005, Pembrolizumab, and others.

Brain Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Brain Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Brain Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Brain Cancer market.

Download our free sample page report on Brain Cancer pipeline insights @ https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Brain Cancer Emerging Drugs

ANG1005: Angiochem
Pembrolizumab: Merck Sharp & Dohme

Brain Cancer Companies

Over 10 major companies are working on developing therapies for brain metastasis from breast cancer. Among these, Angiochem has drug candidates for brain metastasis from breast cancer in the most advanced stage, namely Phase III.

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Brain Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Brain Cancer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Brain Cancer Therapies and Key Companies: Brain Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Brain Cancer Pipeline Therapeutic Assessment
• Brain Cancer Assessment by Product Type
• Brain Cancer By Stage
• Brain Cancer Assessment by Route of Administration
• Brain Cancer Assessment by Molecule Type

Download Brain Cancer Sample report to know in detail about the Brain Cancer treatment market @ Brain Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Brain Cancer Current Treatment Patterns
4. Brain Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Brain Cancer Late-Stage Products (Phase-III)
7. Brain Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Brain Cancer Discontinued Products
13. Brain Cancer Product Profiles
14. Brain Cancer Key Companies
15. Brain Cancer Key Products
16. Dormant and Discontinued Products
17. Brain Cancer Unmet Needs
18. Brain Cancer Future Perspectives
19. Brain Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Brain Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.